Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Invested Capital (2022 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Return on Invested Capital for 4 consecutive years, with 0.05% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Invested Capital rose 13.0% year-over-year to 0.05%, compared with a TTM value of 0.05% through Jun 2025, up 13.0%, and an annual FY2024 reading of 0.17%, up 4.0% over the prior year.
  • Return on Invested Capital was 0.05% for Q2 2025 at Xeris Biopharma Holdings, up from 0.11% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.05% in Q2 2025 and bottomed at 0.61% in Q1 2022.
  • Average Return on Invested Capital over 4 years is 0.29%, with a median of 0.24% recorded in 2023.
  • The sharpest move saw Return on Invested Capital skyrocketed 32bps in 2023, then rose 3bps in 2024.
  • Year by year, Return on Invested Capital stood at 0.38% in 2022, then skyrocketed by 40bps to 0.23% in 2023, then rose by 27bps to 0.17% in 2024, then skyrocketed by 73bps to 0.05% in 2025.
  • Business Quant data shows Return on Invested Capital for XERS at 0.05% in Q2 2025, 0.11% in Q1 2025, and 0.17% in Q4 2024.